Search Results - "Li, B.T."

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies by Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A., Wolchok, J.D.

“…Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple…”
Get full text

Characterization of on-target adverse events caused by TRK inhibitor therapy by Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A.

“…The tropomyosin receptor kinase (TRK) pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse…”
Get full text

Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies” by Naidoo, J., Page, D.B., Li, B.T., Connell, L.C., Schindler, K., Lacouture, M.E., Postow, M.A., Wolchok, J.D.

Get full text

A dissolution-diffusion sliding model for soft rock grains with hydro-mechanical effect by Z. Liu, C.Y. Zhou, B.T. Li, Y.Q. Lu, X. Yang

“…The deformation and failure of soft rock affected by hydro-mechanical (HM) effect are one of the most concerns in geotechnical engineering, which are basically…”
Get full text

Light trapping in ultrathin plasmonic solar cells by Ferry, Vivian E, Verschuuren, Marc A, Li, Hongbo B T, Verhagen, Ewold, Walters, Robert J, Schropp, Ruud E I, Atwater, Harry A, Polman, Albert

“…We report on the design, fabrication, and measurement of ultrathin film a-Si:H solar cells with nanostructured plasmonic back contacts, which demonstrate…”
Get full text

Disparities in Stage at Presentation among Hispanic and Latinx Patients with Non-Small Cell Lung Cancer by Dee, E.C., Swami, N., Li, B.T., Florez, N., Gomez, D.R.

“…Hispanic and Latinx people in the United States comprise 19% of the population and are the fastest-growing ethnic group. However, prior studies in non-small…”
Get full text

Sotorasib for Lung Cancers with KRAS p.G12C Mutation by Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy

“…Sotorasib is a selective irreversible inhibitor of the G12C-activated KRAS oncogene, present in approximately 13% of non–small-cell lung cancers. In a…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors by Kris, M.G., Camidge, D.R., Giaccone, G., Hida, T., Li, B.T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M.E., Goldberg, Z., Jänne, P.A.

“…HER2 mutations and amplifications have been identified as oncogenic drivers in lung cancers. Dacomitinib, an irreversible inhibitor of HER2, EGFR (HER1), and…”
Get full text

Expanding the nanotherapeutic toolbox for non-small-cell lung cancer by Jee, J., Li, B.T.

Get full text

Chemotherapy remains an essential element of personalized care for persons with lung cancers by Hellmann, M.D., Li, B.T., Chaft, J.E., Kris, M.G.

“…Molecularly targeted and immunotherapies have improved the care of patients with lung cancers. These successes have rallied calls to replace or avoid…”
Get full text

Hot wire CVD deposition of nanocrystalline silicon solar cells on rough substrates by Li, Hongbo B.T., van der Werf, Karine H.M., Rath, Jatin K., Schropp, Ruud E.I.

“…In silicon thin film solar cell technology, frequently rough or textured substrates are used to scatter the light and enhance its absorption. The important…”
Get full text

Prospective, Cell-Free Circulating Tumor DNA (ctDNA) Profiling in Locally Advanced Lung Cancer Treated with Chemoradiation by Kratochvil, L.B., Lebow, E.S., Eichholz, J., Gelblum, D., Simone, C.B., Shepherd, A.F., Wu, A.J., Shin, J.Y., Rimner, A., Isbell, J., Li, B.T., Shaverdian, N., Gomez, D.R.

“…Liquid biopsy for cell-free circulating tumor DNA (ctDNA) allows for non-invasive, comprehensive genomic profiling. We explored the utility prospective liquid…”
Get full text

NURBS-based IGA of viscous fluid movement with special-shaped small gaps in hybrid bearing by Liu, C., Pei, S.Y., Li, B.T., Liu, H.L., Hong, J.

“…•The problem of viscous fluid flow in hybrid bearing is solved using high-order IGA.•An IGA based hybrid bearing Reynolds equation solution framework is…”
Get full text

502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors by Hong, D.S., Papadopoulos, K., Kim, D.W., Parikh, A., Barve, M., Powderly, J., Starodub, A., Strickler, J., Li, B.T., Oberstein, P., Yu, W., Bitman, B., Lally, S., Lin, W., Sohoni, S., Spira, A.

Get full text

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium by Li, B.T., Janku, F., Jung, B., Hou, C., Madwani, K., Alden, R., Razavi, P., Reis-Filho, J.S., Shen, R., Isbell, J.M., Blocker, A.W., Eattock, N., Gnerre, S., Satya, R.V., Xu, H., Zhao, C., Hall, M.P., Hu, Y., Sehnert, A.J., Brown, D., Ladanyi, M., Rudin, C.M., Hunkapiller, N., Feeney, N., Mills, G.B., Paweletz, C.P., Janne, P.A., Solit, D.B., Riely, G.J., Aravanis, A., Oxnard, G.R.

“…Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also…”
Get full text

The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases by Eichholz, J., Gaeta, B., Walch, H., Boe, L., Kratochvil, L., del Balzo, L.A., Yamada, Y., Yu, Y., Zinovoy, M., Gomez, D.R., Imber, B.S., Isbell, J., Li, B.T., Murciano-Goroff, Y., Arbour, K., Schultz, N., Lebow, E.S., Pike, L.R.G.

“…Brain metastases are common in NSCLC with up to 25% of patients having brain metastases (BMs) at the time of diagnosis and 30% developing BMs during their…”
Get full text

151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd) by Smit, E.F., Felip, E., Uprety, D., Nagasaka, M., Nakagawa, K., Paz-Ares, L., Pacheco, J., Li, B.T., Planchard, D., Baik, C.S., Goto, Y., Murakami, H., Pereira, K.M.C., Taguchi, A., Kogo, M., Kuwahara, Y., Zou, M., Feng, W., Tsuchihashi, Z., Jänne, P.A.

Get full text

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 by Li, B.T., Planchard, D., Goto, K., Smit, E.F., De Langen, J., Goto, Y., Ninomiya, K., Kubo, T., Pérol, M., Felip, E., Hayashi, H., Nakagawa, K., Shimizu, J., Nagasaka, M., Pereira, K.M.C., Taguchi, A., Ali, A., Karnoub, M., Yonemochi, R., Jänne, P.A.

Get full text

657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors by Li, B.T., Lee, K-W., Pegram, M., Sharma, M.R., Lee, J., Spira, A.I., Kang, Y-K., Moore, K.N., Rasco, D., Hanna, G.J., Weinberg, B.A., Yu, T., Alonso, M., Ptacek, J., Yin, M., Tapia, C., Xu, L., Perez, E.A., Dumbrava, E.E.

Get full text